玻璃体内注射与糖尿病性黄斑水肿：现有及新的治疗选择。
Intravitreal injections and diabetic macular edema: actual and new therapeutic options.
作者信息
Pescosolido Nicola, Pranno Federica, Buomprisco Giuseppe
机构信息
University "Sapienza" of Rome, Faculty of Medicine and Dentistry, Department of Cardiovascular, Respiratory, Nephrologic, Anesthesiologic and Geriatric Sciences, Viale del Policlinico 155, 00161, Rome, Italy.
出版信息
Curr Diabetes Rev. 2013 Nov;9(6):491-8. doi: 10.2174/15733998113096660083.
The management of diabetic macular edema (DME) has been revolutionized in recent years. Focal and focal/ grid laser photocoagulation have been the mainstay of treatment for DME for much time. However, nowadays, there is growing evidence that intravitreal VEGF-inhibitors (combined or not with laser photocoagulation) provide better visual outcome in patients with diabetic retinopathy. Hence, anti-VEGF injections are considered the new gold standard to treat diabetic macular edema and eyes with a reduced visual function. Further studies assessing different treatment regimens are underway to define better clinical care pathways.
近年来，糖尿病性黄斑水肿（DME）的治疗发生了革命性变化。在很长一段时间里，局部及局部/格栅样激光光凝一直是DME治疗的主要手段。然而，如今越来越多的证据表明，玻璃体内注射VEGF抑制剂（联合或不联合激光光凝）能为糖尿病视网膜病变患者带来更好的视力预后。因此，抗VEGF注射被视为治疗糖尿病性黄斑水肿及视力下降眼睛的新金标准。评估不同治疗方案的进一步研究正在进行中，以确定更好的临床护理路径。
Zotero 插件